AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02447146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lectures on the disease
Description: The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
Study NCT04408235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Low-Dose LMWH: enoxaparin 4000 IU daily; High dose LMWH: 70 IU/kg twice daily
Study NCT01815632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late infusion of autologous marrow
Description: Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
Study NCT03922919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotaxime Injection
Description: Systematic use of cefotaxime.
Study NCT03922919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal swab
Description: Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
Study NCT03922919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal swab
Description: Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
Study NCT03553225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors
Study NCT03553225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concord Grape extract 1
Description: 1 g Concord Grape extract in 2 capsules
Study NCT03553225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concord Grape extract 2
Description: 500 mg Concord Grape extract in 2 capsules
Study NCT03922919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime/ceftriaxone
Description: ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
Study NCT00087685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg by mouth Daily
Study NCT03310476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potatoes
Description: Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
Study NCT03636009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concurrent traction and neuromobilization technique
Description: participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
Study NCT03636009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sequential traction and neuromobilization technique
Description: Participants will receive neuromobilzation techniques followed by supine cervical traction
Study NCT03636009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active exercise program
Description: Participants will have 4-5 exercises to perform at each session
Study NCT03636009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active exercise program
Description: Participants will have 4-5 exercises to perform at each session
Study NCT03636009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy to cervical and thoracic spine
Description: Lateral glides to cervical spine and thoracic manipulations
Study NCT03636009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy to cervical and thoracic spine
Description: Lateral glides to cervical spine and thoracic manipulations
Study NCT01369576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3.75-7.5mg 14 doses 4 weeks
Study NCT01369576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: 3.75-7.5mg 14 doses 4 weeks
Study NCT02400879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
Study NCT02400879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane and sufentanil
Description: administering sevoflurane and sufentanil for anesthesia maintenance
Study NCT04070391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin B6
Description: oral administration
Study NCT04070391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: oral administration
Study NCT05016557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: Bolus ingestion of 25g protein
Study NCT03954106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: * Part 1: Defibrotide 2.5 mg/kg/dose or 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7).~* Part 2 Recommended Phase 2 Dose: Defibrotide 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7).
Study NCT02321956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Using ultrasound to determine the size of endotracheal tube
Study NCT04408235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Low-Dose LMWH: enoxaparin 4000 IU daily; High dose LMWH: 70 IU/kg twice daily
Study NCT01121562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
Study NCT02289456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Study NCT02289456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03223701 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion
Description: The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
Study NCT03191591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First 1,000 Days Program Site
Description: Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
Study NCT02075515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine (GSK 1437173A)
Description: 2 doses administered intramuscularly in deltoid region of non-dominant arm.
Study NCT03165292 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: mIBG
Description: Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
Study NCT03165292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
Study NCT03165292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Day 1-3 Thiotepa
Study NCT03165292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: ASCT as soon as radiation level allows it in ARM A
Study NCT00717379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: oral
Study NCT00717379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study NCT00717379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT00717379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT00717379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone or equivalent
Description: oral
Study NCT00717379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or equivalent
Description: oral
Study NCT00717379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: oral
Study NCT00717379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: oral
Study NCT03474458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline
Study NCT02632552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted care transition intervention
Description: In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
Study NCT03474458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care therapy
Description: Standard of care therapy
Study NCT01770717 — intervention group
Intervention type: OTHER
Intervention: Spatial Frequency Domain Imaging
Description: Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
Study NCT02632552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active attention control
Description: In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
Study NCT00181610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Prolactin
Description: 60 mcg/kg every 12 hours
Study NCT00181610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human prolactin
Description: 60 mcg/kg given every 12 hours or every 24 hours
Study NCT00962780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Description: 13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
Study NCT00962780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Description: 23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
Study NCT00962780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
Study NCT00962780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: 1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
Study NCT02896998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal on demand of the syndesmotic screw
Description: The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
Study NCT02896998 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine removal of fhe syndesmotic screw
Description: The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
Study NCT00181610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: twice per day
Study NCT04454593 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study,with no intervention
Study NCT03742947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: peripartum haemostasis
Description: Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
Study NCT03742947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: peripartum haemostasis
Description: Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
Study NCT00447876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
Study NCT00447876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
Study NCT03710304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
Study NCT03710304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid plus misoprostol
Description: 1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
Study NCT03710304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: 400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
Study NCT04569812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Resuscitation
Description: flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
Study NCT01806649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT04252495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: A single oral dose of 25 mg.
Study NCT01293123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: raltegravir 400 mg PO twice daily
Study NCT01293123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: efavirenz 600 mg PO once daily
Study NCT02241460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
Study NCT02241460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Promescent Lidocaine Spray
Description: During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
Study NCT02241460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promescent Lidocaine Spray
Description: During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
Study NCT03364972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
Study NCT03364972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
Study NCT01004159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab with irinotecan
Description: Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
Study NCT04590976 — intervention group
Intervention type: OTHER
Intervention: Semi-Structured Interview Healthcare Professional
Description: Interview
Study NCT04590976 — intervention group
Intervention type: OTHER
Intervention: Semi-Structured Interview Patients
Description: Interview
Study NCT04590976 — intervention group
Intervention type: OTHER
Intervention: Think Aloud Interview Patients
Description: Interview
Study NCT04590976 — intervention group
Intervention type: OTHER
Intervention: Discrete Choice Experiment (DCE) Patients
Description: DCE Questionnaire
Study NCT02144662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5mg ranibizumab intravitreal injection
Study NCT04822090 — intervention group
Intervention type: OTHER
Intervention: Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)
Description: red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange
Study NCT01662752 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine green
Description: Please see arm description
Study NCT01185912 — intervention group
Intervention type: PROCEDURE
Intervention: Ventricle muscle tissue samples
Study NCT04313894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Originated Mesencimal Stem Cell
Description: In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
Study NCT01176955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet survey
Description: A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
Study NCT01176955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benzoyl peroxide 5% gel
Description: Topical benzoyl peroxide 5% gel, to be used once daily to the face.
Study NCT01176955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel
Description: Topical benzoyl peroxide 5% gel, to be used once daily to the face.
Study NCT04672174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Questionnaire: DemTect
Description: Questionnaire is handed out to subjects
Study NCT04620642 — intervention group
Intervention type: BIOLOGICAL
Intervention: Registry
Description: No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
Study NCT00515242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage
Description: therapeutic massage
Study NCT00515242 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: thermotherapy
Description: heat therapy
Study NCT03858504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
Study NCT03858504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.